Finance entity
markets is the sole category represented across all 1 tracked stories. Anbio Biotechnology is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.1.
Last mentioned: Feb 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Anbio Biotechnology is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.1. Each story carries 3 original sources on average, compared with 2.9 for the broader beat in this window. Oncocyte appears in 1 tracked Finance story from February 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 35 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Oncocyte. Shared-story counts are live from our verified record — not editorial picks.
A comprehensive financial comparison between Anbio Biotechnology and Oncocyte reveals divergent strategies within the medical diagnostic manufacturing sector. While both firms compete for institutional capital, their focus on rapid testing versus precision oncology creates distinct risk-reward profiles for investors.
Oncocyte is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
